University of California

Epitomics, Inc.

Other

The Scripps Research Institute

Ventana Medical Systems, Inc.

Robert Pytela

Dean Sheppard

Weimin Zhu

Yaohuang Ke

Qi Qian

Harry C Au

Vito Quaranta

Zhiming Liao

Yifei Zhu

Xiaozhu Huang

Liao Zhiming

The invention provides antibodies immunoreactive with human OX40 and methods of using the same. The antibodies are reactive with a portion of the C-terminus of the human OX40 protein that includes amino acids 266-277. The antibodies are useful for detecting OX40 protein expression in human tissue samples, including by immunohistochemistry, immunofluorescence, or immunoblot.

Anti-OX40 antibodies and diagnostic uses thereof

The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Fusion partner for production of monoclonal rabbit antibodies

Methods and compositions comprising antagonists of &#x3b1;v&#x3b2;6 are provided for the treatment of acute lung injury fibrosis.

Treatment of acute lung injury, fibrosis and metastasis with antagonists of &#x3b1;v&#x3b2;6

The present invention provides substantially pure integrins containing a novel &#x3b2; subunit designated as &#x3b2;. The novel &#x3b2;subunit forms heterodimers with &#x3b1;and &#x3b1;. Methods of controlling cell adhesion using the &#x3b2;-containing integrins are also provided.

[object Object]

The present invention provides substantially pure integrins containing a novel &bgr; subunit designated as &bgr; . The novel &bgr; subunit forms heterodimers with &agr; and &agr; . Methods of controlling cell adhesion using the &bgr; -containing integrins are also provided.

Methods of expressing integrin &bgr;6 subunits

The present invention provides anti-&bgr;6-antibodies that block attachment of &agr;v&bgr;6 to its ligands such as fibronection and tenascin.

Antibodies specifically reactive with integrin &bgr;6 subunits

Methods of decreasing cell adhesion

Methods of detecting &agr;v&bgr;6 ligands

Nucleic acids encoding an integrin &bgr;-subunit, designated &bgr; , are provided along with nucleic acids encoding fragments specific to &bgr; . Also disclosed are vectors containing a gene encoding &bgr; or fragments specific to &bgr; , and hosts containing such vectors. Nucleic acids that specifically hybridize with the disclosed nucleic acids are also provided.

Isolated nucleic acid encoding an integrin &bgr;-subunit

The present invention provides substantially pure integrins containing a novel .beta. subunit designated as .beta..sub.6. The novel .beta..sub.6 subunit forms heterodimers with .alpha..sub.V and .alpha..sub.F. Methods of controlling cell adhesion using the B.sub.6 -containing integrins are also provided.

Growing community of inventors

San Francisco, CA, United States of America

Robert Pytela